Z

Zymeworks Inc
F:0OX

Watchlist Manager
Zymeworks Inc
F:0OX
Watchlist
Price: 26.85 EUR 3.87%
Market Cap: 1.2B EUR

Zymeworks Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zymeworks Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zymeworks Inc
F:0OX
Free Cash Flow
-$122.4m
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Free Cash Flow
-$3.1m
CAGR 3-Years
40%
CAGR 5-Years
10%
CAGR 10-Years
-23%
Repare Therapeutics Inc
NASDAQ:RPTX
Free Cash Flow
-$70.1m
CAGR 3-Years
N/A
CAGR 5-Years
-80%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Free Cash Flow
$119.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Free Cash Flow
-$253.3m
CAGR 3-Years
-42%
CAGR 5-Years
-70%
CAGR 10-Years
-31%
Spectral Medical Inc
TSX:EDT
Free Cash Flow
-CA$9.3m
CAGR 3-Years
2%
CAGR 5-Years
-80%
CAGR 10-Years
0%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1.2B EUR
Industry
Biotechnology

Zymeworks Inc., a clinical-stage biopharmaceutical company, is on a mission to redefine the treatment landscape for serious diseases through its innovative approach to protein engineering and therapeutics. Established in Canada, Zymeworks is at the forefront of creating multifunctional therapeutics designed to combat cancer and other complex diseases. Central to its operation is the proprietary Azymetric™ platform, an advanced technology that enables the development of bispecific antibodies. This platform allows the creation of drugs that can simultaneously target two distinct antigens, vastly improving therapeutic efficacy and minimizing side effects. This groundbreaking technology represents a convergence of advanced science and tailored medicine, with applications that could fundamentally change patient outcomes in oncology and beyond. The business model of Zymeworks is multifaceted, involving both in-house development of therapeutic candidates and collaborative partnerships with major pharmaceutical firms. Revenue generation is primarily driven through strategic alliances, where Zymeworks licenses its technology platforms to industry giants like Merck and Eli Lilly in exchange for milestone payments, royalties, and research funding. These partnerships not only provide financial resources but also validate Zymeworks' scientific advancements and accelerate the global reach of its innovations. Additionally, Zymeworks’ pursuit of developing its own pipeline of drug candidates signifies a dual-path strategy; this not only diversifies its income streams but also positions the company as a leader in the next wave of antibody therapeutics. By effectively leveraging their technology in-house, while capitalizing on external partnerships, Zymeworks seeks to establish a lasting impact in the world of biopharmaceuticals.

0OX Intrinsic Value
Not Available
Z

See Also

What is Zymeworks Inc's Free Cash Flow?
Free Cash Flow
-122.4m USD

Based on the financial report for Dec 31, 2023, Zymeworks Inc's Free Cash Flow amounts to -122.4m USD.

What is Zymeworks Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
8%

The average annual Free Cash Flow growth rates for Zymeworks Inc have been 8% over the past three years .

Back to Top